TY - JOUR
T1 - Usefulness of the ncounter analysis system to monitor immune-related biomarkers in pbmcs during anti-PD-1 Therapy
AU - Morisaki, Takafumi
AU - Kubo, Makoto
AU - Umebayashi, Masayo
AU - Yuan, Yuan
AU - Tsuyada, Akihiro
AU - Tanaka, Hiroto
AU - Koya, Norihiro
AU - Nakagawa, Shinichirou
AU - Morisaki, Takashi
AU - Nakamura, Masafumi
N1 - Funding Information:
The Authors would like to thank Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript. Funding: This work was supported by Japan Society for the Promotion of Science KAKENHI Grant Number 18K08577.
Publisher Copyright:
© 2019 International Institute of Anticancer Research. All rights reserved.
PY - 2019
Y1 - 2019
N2 - Background/Aim: Immune checkpoint inhibitors (ICIs) have dramatically changed the clinical outcomes of advanced tumours. However, biomarkers for monitoring immunological features during immunotherapy remain unclear, especially those in the peripheral blood, which are easily available. This study evaluated the usefulness of nCounter Analysis System in identifying immunological biomarkers in peripheral blood mononuclear cells (PBMCs) during ICI therapy. Patients and Methods: PBMCs from two patients who responded well to ICI therapy were used, and the expression levels of immune-related mRNA and extracellular proteins were analyzed. Results: Changes in the expression levels of 55 genes from pre-treatment to on-treatment were bioinformatically similar between the two cases. The expression levels of PD-1 were consistent with those by flow cytometry analysis, a reliable tool for monitoring various markers. Conclusion: The nCounter Analysis System may be a potent tool to simultaneously investigate genes and proteins on PBMCs as biomarkers during immunotherapy using a small amount of sample.
AB - Background/Aim: Immune checkpoint inhibitors (ICIs) have dramatically changed the clinical outcomes of advanced tumours. However, biomarkers for monitoring immunological features during immunotherapy remain unclear, especially those in the peripheral blood, which are easily available. This study evaluated the usefulness of nCounter Analysis System in identifying immunological biomarkers in peripheral blood mononuclear cells (PBMCs) during ICI therapy. Patients and Methods: PBMCs from two patients who responded well to ICI therapy were used, and the expression levels of immune-related mRNA and extracellular proteins were analyzed. Results: Changes in the expression levels of 55 genes from pre-treatment to on-treatment were bioinformatically similar between the two cases. The expression levels of PD-1 were consistent with those by flow cytometry analysis, a reliable tool for monitoring various markers. Conclusion: The nCounter Analysis System may be a potent tool to simultaneously investigate genes and proteins on PBMCs as biomarkers during immunotherapy using a small amount of sample.
UR - http://www.scopus.com/inward/record.url?scp=85070700235&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070700235&partnerID=8YFLogxK
U2 - 10.21873/anticanres.13628
DO - 10.21873/anticanres.13628
M3 - Article
C2 - 31366554
AN - SCOPUS:85070700235
VL - 39
SP - 4517
EP - 4523
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 8
ER -
